Adrogolide HC1 (ABT-431; DAS-431), a prodrug of the dopamine D1 receptor agonist, A-86929: Preclinical pharmacology and clinical data

CNS Drug Reviews

Volumn 7, Issue 3, 2001, Pages 305-316

  Giardina, William J ^a   Williams, Michael ^b  

^a ABBOTT LABORATORIES   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

ABT 431; Adrogolide; Antiparkinson drug; DAS 431; Dopamine agonist; Dopamine receptor; Parkinson's disease

Indexed keywords

4,5,5A,6,7,11B HEXAHYDRO 9,10 DIHYDROXY 2 PROPYL 3 THIA 5 AZACYCLOPENT 1 ENA[C]PHENANTHRENE; ADROGOLIDE; COCAINE; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; LEVODOPA; ANDROSTA 1,4 DIENE 3,11,17 TRIONE; ANDROSTA-1,4-DIENE-3,11,17-TRIONE; ANDROSTANE DERIVATIVE; DOPAMINE RECEPTOR STIMULATING AGENT; PRODRUG; PYRIDINE DERIVATIVE; TETRALIN DERIVATIVE;

AGING; ANIMAL MODEL; ASTHENIA; COCAINE DEPENDENCE; COGNITIVE DEFECT; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG TOLERANCE; DYSKINESIA; FIRST PASS EFFECT; HEADACHE; HUMAN; LOCOMOTION; MARMOSET; NAUSEA; NONHUMAN; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; REVIEW; SKIN MANIFESTATION; VASODILATATION; VERTIGO; VOMITING; ANIMAL; COGNITION; DRUG EFFECT;

ANDROSTENES; ANIMALS; COCAINE-RELATED DISORDERS; COGNITION; DOPAMINE AGONISTS; HUMANS; PARKINSON DISEASE; PRODRUGS; PYRIDINES; TETRAHYDRONAPHTHALENES;

EID: 0035542733     PISSN: 1080563X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3458.2001.tb00201.x     Document Type: Review

References (37)

1. 1 receptor agonists
2. 1 receptor agonist A-86929 maintains efficacy with repeated treatment in rodent and animal primate models of Parkinson's disease
3. 1 receptor agonist, A-86929, after intravenous administration of ABT-431 to Parkinson's disease patients
4. 1 dopamine receptor agonist treatment of Parkinson's disease
5. 1 dopamine receptor agonists indice forelimb clonus
6. Early idiopathic parkinsonism: Initiation and optimization of treatment
7. 1 receptor stimulation
8. Gingival adhesive systems for sustained-release of ABT-431. Proceeding of 25th International Symposium on Controlled Release of Bioactive Materials, June 21-24
9. 1 receptor agonist A-86929, is inactive in conditioned place preference and self-administration tests of abuse liability
10. Recent advances in the molecular biology of dopamine receptors
11. 1 receptor agonist A-86929: An acute study in parkinsonian levodopa-primed monkeys
12. Parkinson's disease: Prospects for improving drug therapy
13. Effects of pergolide on cocaine self-administration in men and women
14. 1 agonist (ABT-431) on smoked cocaine self-administration in humans
15. Biochemical models of Parkinson's disease
16. 1 receptor agonist with anti-parkinsonian activity in marmosets
17. Bromocriptine and cocaine cue reactivity in cocaine-dependent patients
18. Pergolide mesylate for cocaine abuse: A controlled preliminary trial
19. Dose response effects of pergolide in the treatment of cocaine dependence
20. Problems with long-term levodopa therapy for Parkinson's disease
21. 1 receptor family agonists, SK&F38393, SK&F77434 and SK&F82958, differentially affect locomotor activities in rats
22. (5aR,11bS)-4,5,5a,6,7,11b-Hexahydro-2-propyl-3-thia5-azacyclopent-1-ena[c]- phenanthrene-9,10-diol (A-86929): A potent and selective agonist that maintains behavioral efficacy following repeated administration and characterization of its diacetyl prodrug (ABT-431)
23. 1 agonist
24. Effects of cocaine alone and in combination with bromocriptine in human cocaine abusers
25. 1 receptor agonist prodrug, has efficacy in Parkinson's disease
26. 1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with Parkinson disease
27. Neural substrates of drug craving and relapse in drug addiction
28. 1 agonists SKF 82958 and SKF 77434 are self-administered by rats
29. 2-like dopamine receptor agonists
30. 1 dopamine receptor agonist ABT-431 on cocaine self-administration and reinstatement
31. 1 receptor agonists A-86929 and ABT-431
32. 1 receptor agonist: In vitro characterization and effects in animal models of parkinson's disease
33. Current approaches in the treatment of Parkinson's disease
34. 1 dopamine receptor agonist, in MPTP-treated marmosets and patients with Parkinson's disease
35. An immunohistochemical study of the acute and long-term effects of 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine in the marmoset
36. Intravenous self-administration of dopamine receptor agonists by rhesus monkeys
37. 1 agonist, ABT-431, in dogs and humans